• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Why is buprenorphine coformulated with naloxone?

作者信息

Urnoski Eric

机构信息

Eric Urnoski is a clinical pharmacist in critical care at Crozer-Chester Medical Center in Upland, Pa. The author has disclosed no potential conflicts of interest, financial or otherwise.

出版信息

JAAPA. 2017 Nov;30(11):44-45. doi: 10.1097/01.JAA.0000525919.14882.ed.

DOI:10.1097/01.JAA.0000525919.14882.ed
PMID:29064938
Abstract

Combination buprenorphine-naloxone is a cornerstone of outpatient treatment for substance use disorder, and is more widely accessible in primary care. Because oral buprenorphine has been diverted and abused for its euphoric properties, a combination formulation was developed and will trigger withdrawal symptoms if injected IV.

摘要

相似文献

1
Why is buprenorphine coformulated with naloxone?
JAAPA. 2017 Nov;30(11):44-45. doi: 10.1097/01.JAA.0000525919.14882.ed.
2
Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?丁丙诺啡与纳洛酮组合的临床及药理学评估:为何治疗采用4:1的比例?
Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S29-37. doi: 10.1016/s0376-8716(03)00057-7.
3
Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.丁丙诺啡/纳洛酮在阿片类药物依赖患者中的安全性和疗效:一项意大利观察性研究。
Clin Drug Investig. 2010;30 Suppl 1:21-6. doi: 10.2165/11536010-000000000-00000.
4
Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.从丁丙诺啡转换为丁丙诺啡/纳洛酮在意大利戒毒治疗中心的安全性和耐受性。
Clin Drug Investig. 2010;30 Suppl 1:27-31. doi: 10.2165/11536030-000000000-00000.
5
High-dose buprenorphine for treatment of high potency opioid use disorder.高剂量丁丙诺啡治疗高效阿片类药物使用障碍。
Drug Alcohol Rev. 2020 Feb;39(2):135-137. doi: 10.1111/dar.13017. Epub 2019 Nov 25.
6
Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.从单纯丁丙诺啡转为丁丙诺啡/纳洛酮治疗:意大利戒毒中心的临床经验。
Clin Drug Investig. 2010;30 Suppl 1:13-9. doi: 10.2165/11536040-000000000-00000.
7
Buprenorphine-naloxone.丁丙诺啡-纳洛酮
CMAJ. 2018 Nov 26;190(47):E1389. doi: 10.1503/cmaj.180776.
8
The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible.世事变迁:丁丙诺啡/纳洛酮仍在被转移,而治疗却仍难以获得。
J Addict Med. 2018 Nov/Dec;12(6):459-465. doi: 10.1097/ADM.0000000000000436.
9
Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction.患者是否已准备好迎接变化?:一项评估丁丙诺啡-纳洛酮制剂变化对处方模式、治疗依从性和患者满意度影响的实证研究。
Subst Use Misuse. 2019;54(2):307-314. doi: 10.1080/10826084.2018.1517799. Epub 2018 Dec 4.
10
Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.在意大利,双相丁丙诺啡/纳洛酮每两周一次与丁丙诺啡的临床经验:基于诊所有初步观察数据。
Clin Drug Investig. 2010;30 Suppl 1:33-9. doi: 10.2165/11536060-000000000-00000.

引用本文的文献

1
Narrative review: Managing buprenorphine and opioid use disorder in the perioperative setting.叙述性综述:围手术期丁丙诺啡与阿片类物质使用障碍的管理
Pain Pract. 2025 Jan;25(1):e13427. doi: 10.1111/papr.13427. Epub 2024 Oct 25.
2
Emerging Evidence for Cannabis' Role in Opioid Use Disorder.大麻在阿片类物质使用障碍中作用的新证据。
Cannabis Cannabinoid Res. 2018 Sep 1;3(1):179-189. doi: 10.1089/can.2018.0022. eCollection 2018.